rituximab + bendamustine + prednisone

**Rituximab + bendamustine + prednisone** is a combination regimen used primarily in the treatment of indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. - **Rituximab** is a chimeric monoclonal antibody that specifically binds to the CD20 antigen on B cells, resulting in cell lysis primarily via complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. - **Bendamustine** is a bifunctional alkylating agent that causes intra- and inter-strand cross-links in DNA, resulting in apoptosis of both resting and dividing cells. - **Prednisone** is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects through binding of the glucocorticoid receptor, modulating gene expression that leads to decreased proliferation and survival of lymphoid cells. This regimen may be used as first- or second-line therapy in lymphoid malignancies and is an alternative to other combinations like R-CHOP for specific subtypes. Prednisone is sometimes included to reduce inflammation, modulate immune response, and mitigate some chemotherapy-related side effects[1][3][4].

Other names

R-Benda-PR-bendamustine-prednisonebendamustine rituximab prednisone